AU Patent

AU2013337277B2 — Novel NTRK1 fusion molecules and uses thereof

Assigned to Foundation Medicine Inc · Expires 2018-03-08 · 8y expired

What this patent protects

Novel NTRK1 fusion molecules, detection reagents, and uses and kits for evaluating, identifying, assessing and/or treating a subject having a cancer are disclosed.

USPTO Abstract

Novel NTRK1 fusion molecules, detection reagents, and uses and kits for evaluating, identifying, assessing and/or treating a subject having a cancer are disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
AU2013337277B2
Jurisdiction
AU
Classification
—
Expires
2018-03-08
Drug substance claim
No
Drug product claim
No
Assignee
Foundation Medicine Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.